Literature DB >> 1610254

Bronchial carcinoid tumors: a retrospective analysis of 126 patients.

D H Harpole1, J M Feldman, S Buchanan, W G Young, W G Wolfe.   

Abstract

From 1970 until 1990, 8,958 cases of primary carcinoma of the lung were diagnosed at the Duke University Medical Center. During the same period, 126 patients (mean age, 53 +/- 13 years) were diagnosed with bronchial carcinoid. The overall survival was 78% for 5 years and 71% for 10 years. Surgical treatment in 106 patients included pneumonectomy (15), lobectomy (63 with 9 bronchoplastic procedures), stapled wedge resection (22), and bronchoscopic laser resection (6). The method of diagnosis was chest roentgenography (121), chest computed tomography (77), mediastinal tomography (31), bronchoscopy (81), bronchoscopic brushing and washing (50), bronchoscopic biopsy (40), transthoracic needle biopsy (27), thoracotomy (100), and autopsy (5). Univariate analysis of the medical history, presenting signs and symptoms, diagnostic test results, and pathologic data predicted improved survival (p less than 0.001) for: female sex (n = 58), asymptomatic presentation (n = 47), normal serum serotonin or urinary hydroxyindoleacetic acid levels (n = 76), peripheral location of the primary tumor (n = 50), pathologic stage I or II (n = 91), negative lymph nodes (n = 80), primary tumor 2 cm or less in diameter (n = 67), and typical histology (n = 80). No significance (p greater than 0.1) was observed for age, smoking history, race, family history of carcinoid, environmental exposure, or hemoptysis. The most important factors affecting survival defined by multivariate analysis were (p less than 0.01) pathologic stage, atypical histology, and asymptomatic presentation. Bronchial carcinoid tumors are unique, making up 1% to 2% of primary lung neoplasms and having an excellent prognosis after resection with a 95% 5-year and 93% 10-year survival for pathologic stage I disease.

Entities:  

Mesh:

Year:  1992        PMID: 1610254     DOI: 10.1016/0003-4975(92)91139-z

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  26 in total

1.  Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience.

Authors:  Ryan F Herde; Kristine E Kokeny; Chakravarthy B Reddy; Wallace L Akerley; Nan Hu; Jonathan P Boltax; Ying J Hitchcock
Journal:  Am J Clin Oncol       Date:  2018-01       Impact factor: 2.339

2.  Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors.

Authors:  Thomas E Clancy; Tanya P Sengupta; Jessica Paulus; Fawzia Ahmed; Mei-Sheng Duh; Matthew H Kulke
Journal:  Dig Dis Sci       Date:  2006-06-07       Impact factor: 3.199

3.  Simulations of virtual PET/CT 3-D bronchoscopy imaging using a physical porcine lung-heart phantom.

Authors:  David Yerushalmi; Rakesh Mullick; Andrew Quon; Rebecca Fahrig; Norbert J Pelc; James I Fann; Sanjiv S Gambhir
Journal:  Mol Imaging Biol       Date:  2009-05-12       Impact factor: 3.488

4.  Carcinoid tumour presenting as recurrent pneumonia.

Authors:  Ruvini Dharmagunawardena; Marc Lipman; Joanne Cleverley; Charlotte Cash
Journal:  BMJ Case Rep       Date:  2013-11-20

Review 5.  Principles of diagnosis and management of neuroendocrine tumours.

Authors:  Michael J Raphael; David L Chan; Calvin Law; Simron Singh
Journal:  CMAJ       Date:  2017-03-13       Impact factor: 8.262

Review 6.  Malignant central airway obstruction.

Authors:  Lakshmi Mudambi; Russell Miller; George A Eapen
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 7.  Management of pulmonary neuroendocrine tumors.

Authors:  Robert A Ramirez; Aman Chauhan; Juan Gimenez; Katharine E H Thomas; Ioni Kokodis; Brianne A Voros
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

Review 8.  Advances in the treatment of neuroendocrine tumors.

Authors:  Matthew Kulke
Journal:  Curr Treat Options Oncol       Date:  2005-09

9.  Survival and Predictors of Death for Patients with Bronchopulmonary Carcinoid at a Danish Tertiary NET Centre.

Authors:  Linda Skibsted Kornerup; Gitte Dam; Henning Gronbaek
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

10.  Gastroenteropancreatic neuroendocrine tumors: 10-year experience in a single center.

Authors:  Ozcan Yildiz; Mustafa Ozguroglu; Teoman Yanmaz; Hande Turna; Suheyla Serdengecti; Gulen Dogusoy
Journal:  Med Oncol       Date:  2009-11-03       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.